The SF‐36 is widely used to evaluate the health‐related quality of life (HRQoL) of patients with musculoskeletal tumors. Instead of typical methods, calculating the SF‐36 Global Score has recently become an increasingly common reporting approach...
http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
https://www.riss.kr/link?id=O107728581
2021년
-
0736-0266
1554-527X
SCI;SCIE;SCOPUS
학술저널
2116-2123 [※수록면이 p5 이하이면, Review, Columns, Editor's Note, Abstract 등일 경우가 있습니다.]
0
상세조회0
다운로드다국어 초록 (Multilingual Abstract)
The SF‐36 is widely used to evaluate the health‐related quality of life (HRQoL) of patients with musculoskeletal tumors. Instead of typical methods, calculating the SF‐36 Global Score has recently become an increasingly common reporting approach...
The SF‐36 is widely used to evaluate the health‐related quality of life (HRQoL) of patients with musculoskeletal tumors. Instead of typical methods, calculating the SF‐36 Global Score has recently become an increasingly common reporting approach. However, numerical changes lack clear clinical relevance. The minimal clinically important difference (MCID) is useful for interpreting changes in functional scores by defining the smallest change patients may perceive as clinically meaningful. The aim of this study is to determine the MCID of the SF‐36 Global Score in orthopedic oncology patients, which has not been reported to date. Three‐hundred ten patients who underwent surgery and completed two surveys during postoperative follow‐up were reviewed. The two most common methods for calculating the SF‐36 Global Score were used: (1) anchor‐based methods and receiver operating characteristic analysis based on one‐half of the SD of change score and standard error of measurement at baseline and; (2) distribution‐based methods. Using anchor‐based methods, the MCIDs of SF‐36 Global Scores #1 and #2 were 2.7 (area under the curve [AUC] = 0.85) and 2.5 (AUC = 0.79) for improvement, and −1.5 (AUC = 0.81) and −0.6 (AUC = 0.83) for deterioration, respectively. Using distribution‐based methods, the MCIDs of SF‐36 Global Scores #1 and #2 were 4.1 and 4.4 by half SD, and 4.1 and 4.5 by standard error of measurement, respectively. Our findings provide benchmark values, which can serve as a reference for future studies in musculoskeletal tumor patients using the SF‐36 Global Score as a single measure for HRQoL.
Issue Information ‐ Editorial Board and TOC